Viral load and resistance markers in the 352-person zidovudine trial
Observational study · 1996
- What was studied
- The same 352 zidovudine-treated participants enrolled in the 1995 placebo-controlled trial.
- Main finding
- Progression to AIDS-related complex, AIDS or death · Across both randomized trial strata, the reanalysis reported a relative hazard of 3.0 favoring thymopentin (p=0.015).
Reported findings and study design
Reported findings
Post hoc analysis of baseline CD4 count, viral load, zidovudine resistance at codon 215 and immune-complex-dissociated p24. The parent trial gave 50 mg thymopentin or placebo subcutaneously three times weekly for up to 48 weeks. Most markers were assayed in stored samples after trial completion.
Population or model The same 352 zidovudine-treated participants enrolled in the 1995 placebo-controlled trial.
Dose, route and schedule
Post hoc analysis of baseline CD4 count, viral load, zidovudine resistance at codon 215 and immune-complex-dissociated p24. The parent trial gave 50 mg thymopentin or placebo subcutaneously three times weekly for up to 48 weeks. Most markers were assayed in stored samples after trial completion.
Protocol source ↗ · Original indexed abstract of the retrospective analysis.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Progression to AIDS-related complex, AIDS or death | Across both randomized trial strata, the reanalysis reported a relative hazard of 3.0 favoring thymopentin (p=0.015). | |
| Baseline factors associated with progression | Codon 215 mutation, viral load ≥20,000 RNA copies/mL and CD4 below 350 cells/µL were associated with progression. Baseline p24 ≥30 pg/mL was inconclusive (p=0.52). |
The treatment analyses were retrospective and used the original randomized cohort. Biomarker subgroup results require independent confirmation. The trial predates current combination HIV therapy.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The treatment analyses were retrospective and used the original randomized cohort. Biomarker subgroup results require independent confirmation. The trial predates current combination HIV therapy.
Related publications may describe some of the same participants or experiments.
Source details
Original indexed abstract of the retrospective analysis.
Sources checked
Added to the library
Citation
T. C. Merigan, R. L. Hirsch, A. C. Fisher, L. A. Meyerson, G. Goldstein, M. A. Winters. Viral load and resistance markers in the 352-person zidovudine trial AIDS 10(2), 159–165
Study source ↗ · DOI 10.1097/00002030-199602000-00005 · Bibliography entry · Link to this summary